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Abstract- Migraine is a common and incapacitating neurologic disorder manifesting with episodic moderate 
to a severe headache and other symptoms such as photophobia, phonophobia, nausea, and vomiting. Triptans 
and ergot compounds have been used as treatment options for an acute migraine headache for many years. 
Triptans are considered the first line of treatment in patients with moderate to a severe migraine. Although the 
triptans are commonly used at any time during a migraine attack; they are more efficacious when used in the 
early stages of a migraine. Intravenous valproic acid has been shown to be well tolerated, safe, and with rapid 
onset of action in patients with acute moderate to severe and even refractory migraine. Sodium valproate is a 
Food and Drug Administration (FDA)–approved drug for prophylaxis of a migraine with and without aura. In 
this study, the main goal was to compare the effectiveness of sumatriptan versus valproate in an acute 
migraine. A randomized clinical trial including 37 patients with an acute migraine was considered to compare 
the effectiveness of sumatriptan versus valproate. The patients were divided into two groups. In first group, 6 
mg subcutaneous of sumatriptan and in the second group 15 mg/Kg of valproate was administered. The 
outcomes including pain and drug adverse effects were compared across the groups. A total of 37 patients (7 
male and 30 female) were evaluated in two groups. The difference between two groups regarding sex and age 
was not significant (P>0.05). The mean pain scores reduced from 8.3 to 4.7 and from 8.3 to 2.2 after one hour 
of treatment in sumatriptan and valproate groups, respectively. Response to treatment in valproate group was 
faster and more effective than sumatriptan group (P<0.05).The results indicated that valproate was more 
effective and with the faster response in patients with an acute migraine in comparison with sumatriptan 
without any recurrence and remarkable side effects. 
© 2015 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2015;53(10):633-636.  
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Introduction 
 
A migraine is one of the most common types of 
chronic pain. A migraine usually presents with episodic 
moderate to a severe headache and other symptoms such 
as photophobia, phonophobia, nausea, and vomiting 
(1,2). Sleep disorders, stress, trauma, smoking, positive 
familial history, and some foods are effective in 
initiation or aggravation of a migraine (3-8). Common 
status and deep impact on daily life are a common cause 
of clinical attention in migraine patients (9,10). Triptans 
and ergot compounds have been used as treatment 
options for an acute migraine headache for many years. 
Triptans are considered the first line of the treatment in 
patients with moderate to a severe migraine. Although 
the triptans are commonly used at any time during a 
migraine attack; they are more efficacious when used in 
the early stages of a migraine and obviously their effects 
are less when a headache is established. In contrast, 
sodium valproate has the advantage that affects even the 
headache is established. Intravenous valproic acid has 
been shown to be well tolerated, safe, and with rapid 
onset of action in patients with acute moderate to severe 
and even refractory migraine. Sodium valproate is a 
Food and Drug Administration (FDA)–approved drug 
for prophylaxis of a migraine with and without aura. 
This drug has not been approved for abortive therapy so 
far. This study was performed to compare the 
effectiveness of valproate versus sumatriptan in an acute 
migraine. 
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Materials and Methods 
 
A total of 44 patients with an acute migraine were 
enrolled in an open-label randomized clinical trial. All 
the participants signed the informed consent form. The 
study was approved by Local Medical Ethics 
Committee, and the Helsinki Declaration was respected 
all over the study (code: 91/D/130/2126). Inclusion 
criteria were a negative history of co-morbid diseases 
such as hypertension, coronary artery disease, liver 
disease, kidney disease, headaches other than a 
migraine, migraine with aura, and pregnant patients. 
Patients who were using oral valproate, sumatriptan, 
ergotamine, injection analgesics, Mono Amino 
Oxidase (MAO)-inhibitors, and Selective Serotonin 
Reuptake Inhibitors (SSRI), along with the patients 
who had hypersensitivity reaction to intravenous 
valproate or subcutaneous sumatriptan were excluded 
from this study. 
Among the patients who attended to two general 
referral hospitals from April, 2012 to July, 2013 with 
acute migraine (according to ICHD2 criteria), 44 
subjects aging from 20 to 60 years were enrolled in this 
study. They suffered from a headache for one hour on 
average. They were randomly assigned to receive either 
6 mg of subcutaneous sumatriptan or 15 mg/Kg of 
intravenous valproate. The outcomes including pain 
severity at 0.5, 1, 2, 4, 24, and 48 hours after injection 
(VAS score was used to migraine severity), other 
concomitant symptoms such as photophobia, 
phonophobia etc. and drug adverse effects were 
compared across the groups. Time for the onset of 
action, duration of drug effect, and recurrence of a 
headache were also evaluated. In required cases, the 
electrocardiogram and brain Computed Tomography 
(CT) scan were performed. Vital signs were also 
recorded across the study. 
Data analysis was performed among 37 patients. 
Seven patients out of 44 were excluded (four patients 
due to incomplete filling the questionnaire and three for 
the use of other drugs before the scheduled treatment). 
Data analysis was performed by SPSS (version 18.0) 
software [Statistical Procedures for Social Sciences; 
Chicago, Illinois, USA]. Chi-Square and Independent-
Sample t- tests were used and were considered 
statistically significant at P values less than 0.05. 
 
Results 
 
Seven subjects (19%) were male, and the mean (± 
standard deviation) age of the patients was 37.42±9.68 
(ranging from 23 to 60 years). Eighteen patients 
received sumatriptan, and 19 subjects underwent 
treatment with valproate. The male/female ratio was 
4/14 and 3/16 in sumatriptan and valproate groups, 
respectively (P = 0.46). The mean (± standard 
deviation) age of the patients was 36.17±7.57 and 
38.61 ± 11.41 in sumatriptan and valproate groups, 
respectively (P=0.45). As shown in (Table 1), the vital 
signs were the same between two groups (P>0.05).  
The mean pain score was alike between groups at the 
baseline except for 0.5 and one hours after injection 
(Table 2). 
 
Table 1. Vital signs in two groups
Parameter  Sumatriptan group Valproate group P. value Mean  Standard deviation Mean  Standard deviation
Systolic blood pressure  111.92 13.62 0.2 9.69 118.16 
Diastolic blood pressure  73.07 12.16 0.8 9 74.16 
Pulse rate  81.76 4.83 0.63 5.29 82.75 
Body temperature  36.98 0.31 0.54 0.29 36.90 
 
 
Table 2. Pain score in two groups (VAS score)
Pain measurement interval 
Sumatriptan group Valproate group
P. value Mean Standard deviation Mean 
Standard 
deviation 
Before Treatment 0.84 1.10 8.31 1.19 8.38 
After 0.5 hour 0.001 3.35 3.31 2.35 6.83 
After 1 hour 0.023 3.03 2.26 3.25 4.72 
After 2 hours 0.30 2.91 2.15 2.91 3.16 
After 4 hours 0.99 2.94 2.10 2.76 2.11 
After 24 hours 0.68 2.68 1.68 2.79 2.05 
After 48 hours 0.46 2.38 1.31 2.83 1.94 
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The concomitant symptoms were similar at baseline, 
but responded better to the treatment after 0.5 and one 
hours and were alleviated after 0.5 and one hours (Table 
3 - P<0.05). The most difference (decrease of pain 
score) in the mean of both groups was related to the 
difference between 0.5 and 1 hour (Table 4). Lack of 
response was seen in three and two patients in 
sumatriptan and valproate groups, respectively (P=0.15). 
Only two patients in sumatriptan group had a recurrence 
(P=0.15). The mean (± standard deviation) effect onset 
time was 70.00 ± 60.11 minutes and 22.67± 18.68 
minutes in sumatriptan and valproate groups, 
respectively (P=0.04). No drug adverse effects were 
seen in both groups.  
 
Table 3. Frequency of concomitant symptoms 
Pain M. I. Symptoms Sumatriptan group 
Valproate 
group P. value 
Before treatment 
Photophobia 12 (67%) 11 (58%) 0.8 
Phonophobia 12 (67%) 11 (58%) 0.5 
Nausea 18 (100%) 12 (63%) 0.004 
Vomiting 14 (78%) 1 (5%) 0.1 
After 0.5 hour 
Photophobia 8 (44%) 0 0.005 
Phonophobia 9 (50%) 0 0.001 
Nausea 17 (94%) 0 0.001 
Vomiting 13 (72%) 0 0.001 
After 1 hour 
Photophobia 5 (28%) 0 0.01 
Phonophobia 6 (33%) 0 0.006 
Nausea 12 0 0.001 
Vomiting 8 0 0.001 
 
 
Table 4. Difference (decrease) of the pain score in two groups 
Pain measurement interval  Sumatriptan group Valproate group 
P. Value S. D. Mean P. value S. D. Mean 
Before treatment and after 0.5 hour  0.001 3.75 5.00 0.01 2.45 1.55 
After 0.5 hour and after 1 hour  0.004 2.17 1.05 0.004 2.65 2.11 
After 1 hour and ater 2 hour  0.016 1.10 0.10 0.016 2.45 1.55 
After 2 hours and after 4 hour  0.02 0.22 0.05 0.23 1.79 1.05 
After 4 hours and after 24 hour  0.30 1.26 0.42 0.33 0.23 0.05 
After 24 hours and after 48 hour  0.30 1.60 0.36 0.33 0.47 0.11 
 
Discussion 
 
The disabling pain of migraine attack is the leading 
cause of the need to treatment. Sometimes the severity 
of a headache especially when episodes are frequent 
may interfere with daily activity and result in some 
emotional problems for patients. Decreased self-esteem 
and cognitive problems are common consequences. 
Consequently, the treatment of the disease is necessary. 
In this study, the efficacy of sumatriptan and valproate 
were compared in patients with an acute migraine. In 
previous studies as well as our study, the migraine 
prevalence was more common in women (11). The mean 
age of the patients was 37 years showing the patients 
were mainly young adults. 
We could match the age and the sex across the 
groups to increase the reliability of the results. In both 
groups, the pain score were reduced after treatment with 
a significant difference in before and after treatment 
phases and also up to four hours. The pain score showed 
more reduction with the faster response in valproate 
group compared to sumatriptan. The most decrease in 
pain score in sumatriptan group was after one hour with 
a mean reduction of 2.11 and it was after 0.5 hours with 
a mean reduction of 5 in a score of valproate group. 
Lack of therapeutic response was more common in 
sumatriptan group. The mean onset time was 
significantly shorter in the valproate group. Also, only 
two patients had recurrence both in sumatriptan group. 
Interestingly no therapeutic adverse effects were seen. 
Most studies have shown similar results. Valproate has 
been reported to be rapid onset potent anti-migraine 
medication in previous studies (11-16). Bakhshayesh et 
al,. compared valproate, sumatriptan, and 
metoclopramide for an acute migraine and it was seen 
that valproate had more efficacies in comparison with 
two other drugs (17). Pain severity reduction was seen in 
53% and 23% in valproate and sumatriptan groups, 
respectively in their study. However, the contributing 
percents were 87% and 50% in a current study showing 
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better outcomes in the current investigation. 
Dizziness, mood alterations, blurred vision, 
abnormal eye movements, diplopia, flutter in visual 
field, increased epileptic attacks, abnormal bruise or 
bleeding, lack of appetite, nausea and vomiting, and 
severe abdominal pain are among most common drug 
adverse effects due to valproate use. However, this study 
and the report by Bakhshayesh et al., showed none of 
them in patients. Valproate had a good safety in the 
present study. None of the patients in both groups were 
excluded due to discontinuation of drugs for 
experiencing side effects in this study. 
Photophobia and phonophobia were the most 
common accompanying symptoms that showed a good 
response to valproate and were alleviated after half an 
hour. However, in sumatriptan group these symptoms 
were not alleviated as valproate group and remained in 
some amounts. The study by Yurekli et al., inversely 
reported that general pain was not significantly reduced 
in patients who used valproate (18). These different 
results may be due to selection differences between 
studies or various used designs or even different 
efficacies due to the use of drugs made by different 
companies. It is better to perform similar studies with a 
similar design, study population and drugs preparations 
to obtain more definite and probably congruent results.  
One of the main restraints in this study was small 
sample size that was relatively seen in other studies 
and may decrease the ability to the generalization of 
results. Also the lack of a control group reduced our 
ability to rule of the role of spontaneous improvement 
in some cases. Measurement of a placebo effect or 
even psychological impacts due to the use of injection 
drugs was also not possible. Accordingly, controlled 
larger multi-center studies may help for determination 
of most effective anti-migraine drugs. 
In conclusion, valproate is more effective and has a 
faster response in patients with acute migraine attack in 
comparison with sumatriptan. No remarkable side 
effects are seen in the patients but two patients in 
sumatriptan group had a recurrence. 
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